v3.26.3
Significant Accounting Policies
9 Months Ended
Sep. 30, 2026
Significant Accounting Policies [Abstract]  
SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 - SIGNIFICANT ACCOUNTING POLICIES:

 

  a. Interim condensed consolidated financial statements preparation

 

The interim condensed consolidated financial statements included herein have been prepared in accordance with United States generally accepted accounting principles (“U.S. GAAP”) and on the same basis as the audited consolidated financial statements included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 (the “2025 Form 10-K”). These interim condensed consolidated financial statements reflect all adjustments that are of a normal recurring nature and that are considered necessary for a fair statement of the results of the periods presented. Certain information and disclosures normally included in annual consolidated financial statements have been omitted in this interim period report pursuant to the rules and regulations of the Securities and Exchange Commission. Because the condensed consolidated interim financial statements do not include all of the information and disclosures required by U.S. GAAP for annual financial statements, they should be read in conjunction with the audited consolidated financial statements and notes included in the 2025 Form 10-K. The results for interim periods are not necessarily indicative of a full fiscal year’s results.

 

  b. Recently issued accounting pronouncements adopted

 

In July 2025, the FASB issued ASU 2025-05 “Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets”. The ASU introduces a practical expedient for all entities when estimating expected credit losses for current accounts receivable and current contract assets arising from transactions accounted for under ASC 606. Under the practical expedient, when developing a reasonable and supportable forecast as part of estimating expected credit losses, an entity may assume that current conditions as of the balance sheet date do not change for the remaining life of the asset. The ASU is effective for annual reporting periods beginning after December 15, 2025 and interim reporting within those annual reporting periods. The adoption of ASU 2025-05 did not have a material impact on the Company’s consolidated financial statements.

 

  c. Recently issued accounting pronouncements, not yet adopted

 

In November 2024, the FASB issued ASU 2024-03 “Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses”, which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement as well as disclosures about selling expenses. ASU 2024-03 is effective for years beginning after December 15, 2026, and interim periods within years beginning after December 15, 2027, with early adoption permitted, and may be applied either prospectively or retrospectively. The Company is currently evaluating this guidance to determine the impact it may have on its consolidated financial statements disclosures.

 

 In September 2025, the FASB issued ASU No. 2025-07 (“ASU 2025-07”), Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606). The guidance refines the scope of Topic 815 by clarifying which contracts are subject to derivative accounting and expands the scope exception for certain contracts not traded on an exchange to include contracts for which settlement is based on operations or activities specific to one of the parties to the contract. The guidance also provides clarification under Topic 606 for share-based payments from a customer in a revenue contract. The amendments in ASU 2025-07 are effective for annual periods beginning after December 15, 2026, and interim reporting periods within those annual reporting periods. Early adoption is permitted. The amendments may be applied prospectively or on a modified retrospective basis. The Company is currently evaluating the potential impact of this guidance on its consolidated financial statements.

 

  d. Fair value

 

The Company measures fair value and discloses fair value measurements for financial assets and liabilities. Fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows:

 

  Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

 

  Level 2: Observable prices that are based on inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

 

  Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

 

The Company’s financial assets subject to fair value measurements on a recurring basis and the level of inputs used in such measurements were as follows:

 

    September 30, 2026  
    Level 1     Level 2     Level 3     Total  
Assets:                        
Marketable Securities (see note 3):                        
DNA     583       -       -       583  
Nano     10,801       -       -       10,801  
Investments at fair value (see note 4):                                
Ruby Capital     -       -       449       449  
Scilex Royalty Purchase Agreement     -       -       1,749       1,749  
Scilex Tranche A Note     -       -       18,716       18,716  
Scilex Tranche B Note     -       -       4,591       4,591  
Scilex Warrants Note B     -       -       97       97  
Lifeward’s A&R Warrants (see note 8)     -       -       1,675       1,675  
Lifeward’s A&R Note and Note Warrants (see note 8)     -       -       7,857       7,857  
Alpha Tau’s warrants     -       -       36,626       36,626  
Warren at Bay Loan     -       -       2,703       2,703  
83 Wythe Loan     -       -       2,341       2,341  
Profit Sharing Loan Agreement     -       -       3,338       3,338  
Loan agreement measured in fair value (see note 7)     -       -       37,883       37,883  
Loan to an Equity Method Investee (see note 6)     -       -       4       4  
Investment in associates at fair value (see note 8):                                
Alpha Tau’s shares     215,739       -       -       215,739  
Lifeward’s shares     8,252       -       -       8,252  
Lifeward’s A&R Pre-Funded Warrants     -       6,640       -       6,640  
    $ 235,375     $ 6,640     $ 118,029     $ 360,044  

 

    December 31, 2025  
    Level 1     Level 2     Level 3     Total  
Assets:                        
Marketable Securities (see note 3):                        
DNA     540       -       -       540  
Entera     227       -       -       227  
Pelthos     4,650       -       -       4,650  
Nano     8,371       -       -       8,371  
Investments at fair value (see note 4):                                
Scilex Royalty Purchase Agreement     -       -       2,209       2,209  
Scilex Tranche A Note     -       -       23,063       23,063  
Scilex Warrants Note B     -       -       850       850  
Scilex Tranche B Note     -       -       11,473       11,473  
Loan agreement measured in fair value (see note 7)     -       -       27,943       27,943  
Investment in Alpha Tau’s warrants (see note 8)     -       -       6,242       6,242  
Profit Sharing Loan Agreement     -       -       1,890       1,890  
Investment in Alpha Tau’s shares (see note 8)     71,623       -       -       71,623  
Loan to an equity method investee (see note 6)     -       -       553       553  
Convertible note (see note 8)     -       -       4,636       4,636  
    $ 85,411     $ -     $ 78,859     $ 164,270  

 

As of September 30, 2026 and December 31, 2025, the carrying amounts of cash equivalents, short-term deposits, other current assets, related parties and accounts payable approximate their fair values due to the short-term maturities of these instruments.

 

The amounts funded in respect of employee rights are stated at cash surrender value which approximates its fair value.

 

  e. Other income:

 

1. Alpha Tau

 

The Company recognizes income from its Services Agreement with Alpha Tau for investor relations and public relations on a straight-line basis. Under the Services Agreement, the Company received non-cash consideration of Alpha Tau Warrants (as defined below) to purchase up to 3,237,000 shares, measured at their issuance date fair value of $2,727, and is entitled to receive six semi-annual payments of $500, totaling $3,000. The income is presented under the “Other income, net” line item (net of related expenses), since the Company does not view investor relations services to be output of its ordinary activities. In addition, changes in the fair value of the Alpha Tau Warrants are presented under Financial income, net.

 

During the nine and three months ended September 30, 2026, the Company recognized income of $750 and $250, respectively, under the Services Agreement and $682 and $227, respectively, in respect of the Alpha Tau Warrants, totaling $1,432 and $477, respectively. Net of related investor relations expenses of $176 and $68, respectively, the Company recognized $1,256 and $409, respectively, under “Other income, net”. As of September 30, 2026, the remaining deferred income balance was $63, which was presented under “Deferred income”. For further details, see Note 8.

 

2. Capital Gain from Sale of IP

 

In connection with the Share Purchase Agreement (see note 1 above), the Company recognized a gain of $5,821 on sale of the IP from the Subsidiary, which is presented within “Other income, net” in the consolidated statements of operations.

 

3. Clinical Trial Management Agreement with OraTech

 

In connection with the Share Purchase Agreement, the Company entered into a Clinical Trial Management Agreement with OraTech (the “Clinical Trial Management Agreement”), pursuant to which the Company is contractually obligated to manage the clinical study of OraTech’s investigational oral insulin capsule product (the “Study”), including the provision of clinical trial management and administrative services through completion of the Study (the “Services”). The Clinical Trial Management Agreement will terminate upon completion of the Study, unless earlier terminated in accordance with its terms.

 

Prior to the Lifeward Closing Date, the Company funded OraTech with $6,500 in cash, intended to fund the Study. Under the Clinical Trial Management Agreement, OraTech will pay the Company for the Services out of such funds, including reimbursement of reasonable out-of-pocket expenses actually incurred by the Company in providing the Services and payments made by the Company on behalf of OraTech to third parties and vendors.

 

During the period from March 25, 2026 (the Lifeward Closing Date) through September 30, 2026 and during the three months ended September 30, 2026, the Company charged OraTech $1,114 and $492, respectively, for services and expenses incurred under the Clinical Trial Management Agreement and recognized a corresponding related-party receivable. Together with the recognition of the deferred income described below, income related to the Clinical Trial Management Agreement amounted to $270 and $78 for the nine and three months ended September 30, 2026, respectively (see Note 14).

 

To the extent the actual cost of the Study exceeds $6,500, the Company will bear such excess costs without additional consideration from Lifeward or OraTech. Based on the Company’s current estimates, the Company does not expect the actual cost of the Study to exceed $6,500. The Company recognized $975 as deferred income in connection with the Clinical Trial Management Agreement on the Lifeward Closing Date. The deferred income is recognized as the related services are provided and presented within “Other Income, Net” in the Company’s consolidated statements of operations.

 

During the nine and three months ended September 30, 2026, the Company recognized $167 and $74, respectively, of the deferred income as Other Income, Net in the consolidated statements of operations. As of September 30, 2026, the deferred income balance was $808.

 

4. Medicox

 

On November 13, 2022, the Company entered into a ten-year distribution license agreement (“Medicox License Agreement”) with Medicox Co., Ltd. (“Medicox”), pursuant to which the Company granted Medicox an exclusive license to apply for regulatory approval and distribute ORMD-0801 in the Republic of Korea.

 

The Medicox License Agreement contains a fixed non-refundable consideration of $2,000, which was received by the Company during the year ended December 31, 2022. The Company’s performance obligation consisted of a stand-ready obligation to support Medicox, and the related consideration was to be recognized as revenue on a straight-line basis over the period during which the Company expected to provide such support.

 

As such support had not commenced, the consideration was presented as long-term deferred revenue on the consolidated balance sheet as of December 31, 2025.

 

Following the Lifeward transaction (see note 8) the expected clinical development timeline for the approval of ORMD-0801 was extended beyond the term contemplated under the Medicox License Agreement. Consequently, the Company concluded that the agreement was no longer commercially viable and that there was no remaining performance obligation to fulfill under it.

 

Accordingly, during the nine months ended September 30, 2026, the Company recognized income associated with the Medicox License Agreement in an amount of $2,000 under “Other income, net” in the consolidated statements of operations.

 

5. Lifeward Revenue Share

 

The Company has determined that the Lifeward Revenue Share payments represent variable consideration associated with the transfer of intellectual property and accounts for these amounts by analogy to the variable consideration guidance in ASC 606. The Company concluded that the sales- or usage-based royalty exception under ASC 606 does not apply, as the underlying transaction represents a sale of intellectual property rather than a license of intellectual property. Accordingly, amounts are included in the measurement of consideration only to the extent that it is probable that a significant reversal of cumulative consideration recognized will not occur when the underlying sales-based uncertainty is subsequently resolved.

 

  f. Investment in associate at fair value- Lifeward

 

In connection with the Share Purchase Agreement and the Lifeward Notes Purchase Agreement (see Note 1 above), Lifeward issued the following components to the Company, each of which is accounted for as described below:

 

1. Lifeward Ordinary Shares and other financial instruments

 

The Company has determined that Lifeward is a variable interest entity (“VIE”) for which the Company is not the primary beneficiary, as it does not have the power to direct the activities that most significantly impact Lifeward’s economic performance. Accordingly, the Company does not consolidate Lifeward. The Company has significant influence over Lifeward. The Company elected the fair value option under ASC 825 for this investment.

 

The investment was initially measured at fair value based on the quoted closing price of Lifeward’s Ordinary Shares on the Lifeward Closing Date, with subsequent changes in fair value recognized in financial income, net, in the consolidated statements of comprehensive income.

 

As of September 30, 2026, the carrying amount of the Company’s interests in unconsolidated VIEs was $24,897, which also represented the Company’s maximum exposure to loss, except that the Company may be required to fund the Additional Notes and Additional Note Warrants upon the occurrence of certain conditions. See Note 1 for further information and Note 8, “Investment in Associate at Fair Value.”

 

Because the Company elected the fair value option for the investment in Lifeward’s Ordinary Shares that would otherwise be accounted for under the equity method, the Company has applied the fair value option to all of its eligible financial interests in Lifeward in accordance with ASC 825. As a result, all of the Company’s financial interests in Lifeward that are eligible items (A&R Pre-Funded Warrants, A&R Warrants, A&R Note and Note Warrants, Additional Notes and the Additional Note Warrants) are measured at fair value recognized in financial income, net, in the consolidated statements of comprehensive income.

 

Summarized financial information for Lifeward, as determined in accordance with Rule 8-03(b)(3) of Regulation S-X is included in note 8.

 

  g. Income per share of common stock

 

Basic income per common stock is computed by dividing the net income attributable to stockholders for the period by the weighted average number of shares of common stock outstanding for each period, including vested restricted stock units (“RSUs”). The Company applies the two-class method in calculating net income per common stock. The two-class method is an earnings allocation formula that calculates basic and diluted net income per share for each class of common stock separately based on participation rights in undistributed earnings. Unvested share-based payment awards that contain nonforfeitable rights to dividends are treated as participating securities and therefore included in computing net income per share using the two-class method. The net income available to common stockholders is reduced by dividend equivalents declared on unvested RSUs, as such awards are not considered participating securities and are excluded from the basic share count.

 

For the diluted income per common stock calculation. The weighted average number of shares outstanding during the period is adjusted for the potential dilution that could occur in connection with employee share-based payment, using the treasury stock method. Other options to purchase common stock and warrants were considered antidilutive and therefore excluded from the calculation of diluted weighted average shares outstanding. For further details, see Note 13.